title: A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.
abstract: Since intravesical recurrence of superficial bladder cancer (Ta, T1) after transurethral resection (TUR) is frequent, adjuvant therapy to reduce the recurrence rate has been extensively investigated. Although intravesical chemotherapy has been employed for 30 years or more, neither the exact effect on the bladder epithelium nor the optimal dose and administration schedule has yet been clarified. In recent years, several derivatives of Adriamycin (ADR) have been developed, and 4'-epirubicin (FARM) is one of them. This drug has been shown to have antitumor effects almost equal to those of ADR and to produce less toxicity when given systemically as chemotherapy. In an attempt to clarify the effect of intravesical FARM in the prevention of recurrence of superficial bladder cancer, we conducted a prospective randomized trial to compare the effects of equal doses of FARM and ADR given by intravesical instillation after TUR in cases of highly recurrent superficial bladder cancer. A total of 73 patients with recurrent superficial bladder cancer were randomized to receive TUR and either 30 mg FARM or 30 mg ADR by intravesical instillation every 2-4 weeks for 1 year. The prophylactic effect on recurrence and the toxic effects of these drugs were investigated. The current results show that FARM provides efficacy almost equal to that of ADR in the prevention of recurrence in these patients. However, FARM also caused almost the same local toxic effects (bladder irritation, among others) as ADR. On the basis of these preliminary results, FARM is surmised to be one of the agents as beneficial as ADR in the prevention of recurrence of superficial bladder cancer.
authors.affiliation: Department of Urology, Yokohama City University, School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shuin
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
authors.forename: T
authors.initials: T
authors.lastname: Miura
authors.forename: I
authors.initials: I
authors.lastname: Kondo
authors.forename: S
authors.initials: S
authors.lastname: Fukushima
authors.forename: E
authors.initials: E
authors.lastname: Ishizuka
authors.forename: A
authors.initials: A
authors.lastname: Furuhata
authors.forename: M
authors.initials: M
authors.lastname: Moriyama
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D015251:Epirubicin; D004317:Doxorubicin